SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida. The session will take place on Tuesday, March 12, 2024, from 1:40 p.m. to 2:10 p.m., Eastern Daylight ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston. The session will take place on Tuesday, March 5, 2024, from 12:50 p.m. to 1:20 p.m., Eastern Standard Time, and can be accessed v ...

United Therapeutics‘ (UTHR) fourth-quarter 2023 earnings of $4.36 per share beat the Zacks Consensus Estimate of $3.92. Earnings rose 63% year over year on the back of higher product sales.Revenues in the reported quarter were $614.7 million, beating the Zacks Consensus Estimate of $562 million. Revenues rose 25% year over year, driven by Tyvaso sales.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remodulin, Tyvaso, Adcirca and Orenitram. It also marke ...

United Therapeutics (UTHR) closed the last trading session at $219.18, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $290.92 indicates a 32.7% upside potential.The mean estimate comprises 13 short-term price targets with a standard deviation of $50.38. While the lowest estimate of $178 indicates a 18.8% decline from the current price level, the most optimistic analys ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2023 Earnings Call Transcript February 21, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Ash Verma - UBS Jessica F ...

Financial Performance - Total revenue reached $615 million, a 25% year-over-year increase[34] - Tyvaso revenue was $351 million, representing a 45% year-over-year increase[34] - Remodulin revenue was $115 million, a 6% year-over-year increase[34] - Orenitram revenue was $84 million, an 11% year-over-year increase[34] - Unituxin revenue was $54 million, a 48% year-over-year increase[34] - The company's operating cash flow for FY23 was $978 million[24] - The company has $4.9 billion in cash, cash equivalents, and marketable investments[24] Tyvaso DPI - Sagard Healthcare Partners acquired a 1% royalty interest in Tyvaso DPI from MannKind for $150 million plus other milestones[13] - The company highlights an implied Tyvaso DPI revenue valuation of over $15 billion based on a deal executed after an appeals court ruling, where a 1% royalty equated to $150 million[114] Clinical Trials and Development - TETON 1 and TETON 2 studies for Idiopathic Pulmonary Fibrosis (IPF) are approximately 70% enrolled[28] - The ADVANCE OUTCOMES study for PAH is targeted for trial completion in 2025[31]

For the quarter ended December 2023, United Therapeutics (UTHR) reported revenue of $614.7 million, up 25.1% over the same period last year. EPS came in at $4.36, compared to $2.67 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $561.77 million, representing a surprise of +9.42%. The company delivered an EPS surprise of +11.22%, with the consensus EPS estimate being $3.92.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of record revenue,” said Martine Rothblatt, Ph. ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 OR Delaware 52-1984749 (State or Other Jurisdiction of Incorporation or Organization) 1000 Spring ...

Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 21, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. "Congratulations to the dedicated Unitherians who worked t ...